Skip to main content
. 2006 Sep 1;116(9):2552–2561. doi: 10.1172/JCI28371

Figure 6. Vasorelaxing effects of BAY 58-2667 in vitro and in vivo.

Figure 6

(A) BAY 58-2667–induced relaxation of PE precontracted aorta from Wistar rats (circles) and aged SHR (triangles) with (open symbols) and without (filled symbols) ODQ. (B) BAY 58-2667– (triangles) or SNP–induced (squares) inhibition of PE precontracted saphenous arteries from NZW (filled symbols) and WHHL rabbits (open symbols). (C) BAY 58-2667– (triangles) or GTN-induced (circles) inhibition of U46619 precontracted aorta from ApoE–/–mice on normal (open symbols) or high-fat diet (filled symbols). (D) BAY 58-2667–induced inhibition of PE precontracted human mesocolon arteries from patients with (open circles) and without (filled circles) type 2 diabetes. Means ± SEM of 6–12 vessels shown in A–D. (E) Effect of i.v. BAY 58-2667 (10 μg/kg) with (gray triangles) and without (filled triangles) ODQ pretreatment (2 mg/kg i.v., 10 minutes before BAY 58-2667) or vehicle (open circle) on MAP in anesthetized rats (n = 4). Baseline was 117 ± 3 to 128 ± 4 mmHg. (F) Effect of oral BAY 58-2667 (filled circles, 3.0 mg/kg) and vehicle (open circles) on MAP in conscious Wistar rats. Baseline was 106 ± 4 and 102 ± 3 mmHg (control versus treated, respectively; n = 6). (G) Effect of oral BAY 58-2667 (filled circles, 3.0 mg/kg) and vehicle (open circles) on MAP in conscious SHR. Baseline was 135 ± 11 and 133 ± 4 mmHg (control versus treated, respectively; n = 6). In E–G, predrug values of each group were normalized to 100%. (H) Survival rate in BAY 58-2667–treated (filled circles, 3 mg/kg orally twice daily) and untreated (open triangles) TGR(mRen2)27 under l-NAME. (I) Plasma levels of BNP, renin, creatinine, and urea in BAY 58-2667–treated (black bars) versus control animals (white bars). Values are means ± SEM. ***P < 0.001.